MIF-1 Fact Sheet
- Oxytocin C-terminal tripeptide
- Antidepressant effects
- Nootropic effects
- Anti-Parkinsonian effects
- Antagonism of morphine analgesia
- Muscle mass regulation
MIF-1 Peptide Information
Melanocyte-inhibiting factor-1 (MIF-1), also known as Pro-Leu-Gly-NH2 based on its amino acid structure, is an endogenous peptide fragment that has been shown to have a variety of effects on the central nervous system. It was the first hypothalamic peptide shown to act “up” on the brain, not just “down” on the pituitary.
MIF-1 has been investigated for various medical uses due to its profile of antidepressant, nootropic, and anti-Parkinsonian effects. Clinical studies have shown that MIF-1 can alleviate symptoms in Parkinson’s disease and mental depression.
MIF-1 and Antidepressant Effects
MIF-1, a peptide from the Tyr-MIF-1 family, has been found to have significant effects on stress-induced behaviors. In a study involving rats, the Tyr-W-MIF-1 peptide was found to decrease stress-induced CB1 receptor expression in the periaqueductal gray (PAG) region of the brain, a key area involved in stress-induced analgesia. This suggests that MIF-1 may have potential antidepressant effects by modulating stress responses.
MIF-1 and Nootropic Effects
MIF-1 has been found to activate CNS pathways related to opiate and dopaminergic systems. It can antagonize opiate actions, modulate dopaminergic transmission, and facilitate processes of memory consolidation. However, it does not interact with other aminergic receptors such as adrenergic, GABAergic, or serotonergic receptors.
In the context of MIF-1’s nootropic effects, it has been found to facilitate passive acquisition of brightness discrimination, passive avoidance retention, appetitive maze performance, and inhibits shock-suppressed water intake. These findings are interpreted as contributing to the processes of memory consolidation. This suggests that MIF-1 could potentially be used as a cognitive enhancer, although more research is needed to fully understand its mechanisms and potential applications.
MIF-1 and Anti-Parkinsonian Effects
Research into the use of MIF-1 in the context of Parkinson’s disease is still in its early stages. However, the peptide’s potential role as an opiate antagonist suggests it may have a role in modulating the effects of certain neurotransmitters in the brain. This could potentially have implications for the treatment of Parkinson’s disease, a condition characterized by the loss of dopamine-producing cells.
Please note that while the information provided here is based on current research data, it is not intended to be used for diagnostic or treatment purposes. Always consult with a healthcare professional for medical advice. The use of MIF-1 for research purposes must be done in accordance with appropriate protocols and ethical guidelines. The storage of MIF-1 should be done in a dry, cool place, typically in a lyophilized state in a vial, to maintain its stability and quality.
What is MIF-1 peptide?
MIF-1, also known as Melanocyte-inhibiting factor, is an endogenous peptide fragment that has been shown to have a variety of pharmacological effects on the central nervous system. It is also known as Pro-Leu-Gly-NH, Melanostatin, or MSH release–inhibiting hormone. MIF-1 is unusually resistant to metabolism in the bloodstream and can cross the blood-brain barrier easily.
What are the benefits of MIF-1 peptide?
MIF-1 peptide has been associated with a profile of antidepressant, nootropic, and anti-Parkinsonian effects. It has been investigated for various medical uses, including the treatment of clinical depression and Parkinson’s disease. MIF-1 can also antagonize opiate actions, and it has been shown to modulate dopaminergic transmission, increasing the binding affinity of agonists to the high-affinity state of the dopamine receptor.
What is MIF-1 Tyr peptide?
Tyr-MIF-1 is a variant of MIF-1 that includes an additional tyrosine (Tyr) amino acid at the beginning of the peptide sequence. This peptide not only shows antiopiate activity but also considerable selectivity for the mu-opiate binding site.
Where can I buy MIF-1?
MIF-1 peptide can be purchased from various peptide suppliers including Limitless Life Nootropics. However, it’s important to ensure that the supplier is reputable and provides products with high accuracy and purity.
What is the role of MIF-1 in opiate modulation?
MIF-1 has been shown to antagonize opiate actions, acting as an allosteric modulator. This means it can bind to the opiate receptor and change its shape, inhibiting the effects of opiates. This property has led to the discovery of other endogenous antiopiate peptides.
How is MIF-1 related to hormone regulation?
MIF-1 is also known as MSH release–inhibiting hormone, indicating its role in hormone regulation. It was the first hypothalamic peptide shown to act “up” on the brain, not just “down” on the pituitary, suggesting a specific role in hormone regulation in the brain.
What is the connection between MIF-1 and COVID-19?
There is currently no direct evidence linking MIF-1 to COVID-19. However, given its role in the central nervous system and its potential therapeutic effects, further research may explore its potential applications in the context of neurological symptoms associated with COVID-19.
Who is Bocheva in the context of MIF-1 research?
Bocheva is a researcher who has contributed to the study of MIF-1 and its antiopioid properties. In a study published in 2004, Bocheva and Dzambazova-Maximova explored the antiopioid properties of the TYR-MIF-1 family.
What is the role of MIF-1 in pharmacology?
In pharmacology, MIF-1 is of interest due to its potential therapeutic effects. It has been investigated for various medical uses, including the treatment of clinical depression and Parkinson’s disease. Its ability to antagonize opiate actions and modulate dopaminergic transmission also makes it a subject of interest in the field of pharmacology.